- Home
- EPOW vs BCTX Comparison
EPOW vs BCTX Comparison
Compare EPOW & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EPOW | BCTX |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 28.8M |
| IPO Year | 2019 | 2025 |
Fundamental Metrics
Financial Performance| Metric | EPOW | BCTX |
|---|---|---|
| Price | $0.84 | $4.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 162.5K | ★ 202.7K |
| Earning Date | 05-14-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.61 |
| 52 Week High | $1.86 | $14.68 |
Technical Indicators
Market Signals| Indicator | EPOW | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.27 | 49.74 |
| Support Level | $0.74 | $4.10 |
| Resistance Level | $1.05 | $4.51 |
| Average True Range (ATR) | 0.10 | 0.28 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 28.38 | 57.14 |
Price Performance
Historical ComparisonAbout EPOW Sunrise New Energy Co. Ltd
E Power Inc, through its subsidiaries, is engaged in the manufacturing and sale of graphite anode material for lithium-ion batteries. The company operates a plant in Guizhou Province, China, powered by electricity from renewable sources, which contributes to the plant's low production costs and reduced environmental impact in the production of graphite anode materials. Additionally, it also operates a knowledge sharing platform business.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.